Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: A report of high response rates and prolonged survival

Journal of Clinical Oncology

Volumn 14, Issue 6, 1996, Pages 1913-1921

  Schiller, J H ^a   Storer, B ^a   Berlin, J ^a   Wittenkeller, J ^a   Larson, M ^a,a   Pharo, L ^a   Berry, W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CISPLATIN; VINBLASTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG POTENTIATION; FEMALE; HUMAN; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEPHROTOXICITY; NEUROPATHY; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VOMITING;

EID: 0030013080     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.6.1913     Document Type: Article

References (54)

1. Boring C, Squires T, Tong T: Cancer statistics, 1993. CA 43:7-26, 1993
2. Boring C, Squires T, Tong T, et al: Cancer statistics, 1994. CA 44:7-26, 1994
3. Ruckdeschel J, Finkelstein D, Ettinger D, et al: A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J Clin Oncol 4:14-22, 1986
4. Bonomi PD, Finkelstein D, Ruckdeschel J, et al: Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer. A study of the Eastern Cooperative Oncology Group. J Clin Oncol 7:1602-1613, 1989
5. Weick J, Crowley J, Natale R, et al: A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small cell lung cancer: A Southwest Oncology Group Study. J Clin Oncol 9:1157-1162, 1991
6. Grilli R, Oxman A, Julian J: Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough? J Clin Oncol 11:1866-1871, 1993
7. Schuchter L, Glick J: The current status of WR-2721 (amofostine): A chemotherapy and radiation therapy protector. Biol Ther Cancer Update 1:1-10, 1993
8. Davidson DE, Grenan MM, Sweeney TR: Biological characteristics of some improved radioprotectors, in Brady LW (ed): Radiation Sensitizers. New York, NY, Masson, 1980, pp 309-320
9. Yuhas JM: Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat Rep 63:971-976, 1979
10. Yuhas JM, Culo F: Selective inhibition of the nephrotoxicity of cis-dichlorodiammine-platinum (II) by WR-2721 without altering its antitumor properties. Cancer Treat Rep 64:57-64, 1980
11. Yuhas JM, Spellman JM, Jordan SW: Treatment of tumours with the combination of WR-2721 and cis-dichlorodiammineplatinum (II) or cyclophosphamide. Br J Cancer 42:574-585, 1980
12. Yuhas JM, Storer JB: Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 42:331-335, 1969
13. Wasserman TH, Phillips TL, Ross G, et al: Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by WR-2721. Cancer Clin Trials 4:3-6, 1981
14. Valeriote F, Tolen S: Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 42:4330-4331, 1982
15. Millar JL, McElwain TJ, Clutterbuck RD, et al: The modification of melphalan toxicity in tumor-bearing mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721). Am J Clin Oncol 5:321-328, 1982
16. Treskes M, Boven E, van de Loosdrecht AA, et al: Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer 30A:183-187, 1994
17. Glover D, Glick J, Weiler C, et al: WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma. J Clin Oncol 5:574-578, 1987
18. Avril M, Ortoli J, Fortier-Beaulieu M, et al: High dose cisplatin and WR 2721 in metastatic melanoma. Proc Am Soc Clin Oncol 11:344, 1992 (abstr)
19. Mehta M, Schiller JH, Bastin K, et al: Pilot study of WR 2721/CDDP/VLB and sequential TRT/WR 2721 in stage III NSCLC: preliminary results. Proc Am Soc Clin Oncol 10:263, 1991 (abstr)
20. Mehta M, Storer B, Schiller JH: Phase II study of WR-2721/cisplatin/vinblastine, followed by thoracic radiation (TRT) and WR-2721. in stage II nonsmall cell lung cancer. Proc Am Soc Clin Oncol 12:359, 1993 (abstr)
21. Mehta M, Storer B, Larson M, et al: High response rate for advanced nonsmall cell lung cancer with amifostine, cisplatin, vinblastine, and radiation. Proc Am Soc Clin Oncol 12:349, 1994
22. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
23. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
24. Einhorn L, Loehrer P, Williams S, et al: Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol 4:1037-1043, 1986
25. Luedke D, Sarma P, Greco F, et al: Preliminary report of a randomized trial of vindesine (V) vs V with mitocycin (M) or with cisplatin (C) in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 6:170, 1987 (abstr)
26. Green M, Kramar A, Schilsky R, et al: Platinum-based combination chemotherapy in advanced non-small cell lung cancer: A randomized phase II trial of the Cancer and Leukemia Group B. Med Pediatr Oncol 18:197-202, 1990
27. Kris M, Gralla R, Kalman L, et al: Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat Rep 69:387-395, 1985
28. Le Chevalier T, Brisgand D, Douillard JY, et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced nonsmall cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
29. Le Chevalier T, Pujol JL, Douillard JY, et al: A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of nonsmall cell lung cancer: An expanded analysis. Semin Oncol 21:28-34, 1994 (suppl 10)
30. Paul D, DeVore RD, Hande K, et al: Phase II trial of carboplatin (C) + paclitaxel (T) in advanced nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:361, 1995 (abstr)
31. Langer CJ, Leighton J, Comis R, et al: Paclitaxel (Taxol) and carboplatin (CBDCA) in advanced nonsmall cell lung cancer (NSCLC): Toxicity, response and survival update. Proc Am Soc Clin Oncol 14:355, 1995 (abstr)
32. Rowinsky EK, Sartorious SE, Bowling MK, et al: Paclitaxel on a 3-hour schedule and carboplatin in nonsmall cell lung cancer: Use of maximally tolerated and clinically relevant single agent doses in combination is feasible. Proc Am Soc Clin Oncol 14:354, 1995 (abstr)
33. Vafai D, Israel V, Zaretsky S, et al: Phase I/II trial of combination carboplatin and Taxol in nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:352, 1995 (abstr)
34. Giaccone G, Splinter TAW, Postmus P, et al: Teniposide-cisplatin vs paclitaxel-cisplatin in advanced nonsmall cell lung cancer (NSCLC). Results of a randomized phase II study of the EORTC-LCCG. Proc Am Soc Clin Oncol 14:356, 1995 (abstr)
35. Georgiadis MS, Brown JE, Schuler BS, et al: Phase I study of a four-day continuous infusion of paclitaxel followed by cisplatin in patients with advanced lung cancer. Proc Am Soc Clin Oncol 14:353, 1995 (abstr)
36. Belli L, Le Chevalier T, Gottfried M, et al: Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:350, 1995 (abstr)
37. Zalchberg JR, Bishop JF, Millward MJ, et al: Preliminary results of the first phase II trial of docetaxel in combination with cisplatin in patients with metastatic or locally advanced nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:351, 1995 (abstr)
38. Le Chevalier T, Belli L, Monnier A, et al: Phase II study of docetaxel (Taxotere) and cisplatin in advanced nonsmall cell lung cancer (NSCLC): An interim analysis. Proc Am Soc Clin Oncol 14:350, 1995 (abstr)
39. Cole JT, Gralla RJ, Marques CB, et al: Phase I-II study of cisplatin + docetaxel (taxotere) in nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:357, 1995 (abstr)
40. Crino L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in nonsmall cell lung cancer (NSCLC). A phase II study. Proc Am Soc Clin Oncol 14:352, 1995 (abstr)
41. Shepherd F, Cormier Y, Burkes R, et al: Modified continual reassessment methodology (mCRM): A superior way to assess toxicity in a phase I study of gemcitabine (GEM) and cisplatin (CP) for nonsmall cell lung cancer. Proc Am Soc Clin Oncol 358:14, 1995 (abstr)
42. Al-Sarraf M, Fletcher W, Orshi N: Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A Southwest Oncology Group study. Cancer Treat Rep 66:31-35, 1982
43. Valeriote F, Tolen S: Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res 42:4330-4331, 1982
44. Millar J, McElwain T, Clutterbuck R, et al: The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR 2721). Am J Clin Oncol 5:321-328, 1982
45. Green D, Wright A, Schein PS, et al: WR-2721 chemoprotection of doxorubicin toxicity in mice. Proc Am Assoc Cancer Res 33:490, 1992 (abstr)
46. Douay L, Chen HU, Giarratana MC, et al: Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood 86:2849-2855, 1995
47. Issels RD, Nagele A. Promotion of cystine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminoprophylamino)ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells. Cancer Res 49:2082-2086, 1989
48. Gandara D, Crowley J, Livingston R, et al: Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. J Clin Oncol 11:873-878, 1993
49. Klastersky J, Sculier J, Ravez P, et al: A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 4:1780-1786, 1986
50. Perry D, Krasnow S, Reilly J, et al: Phase II study of cisplatin and etoposide with WR-2721 (Ethyol) for advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 13:359, 1994 (abstr)
51. Mollman JE, Glover DJ, Hogan WM, et al: Cisplatin neuropathy: Risk factors, prognosis and protection by WR-2721. Cancer 61:2192-2195, 1988
52. Alberts DS, Green S, Hannigan EV, et al: Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10:706-717, 1992
53. Capizzi RL, Scheffler BS, Oster W, et al: Amifostine reduces cumulative cisplatin nephrotoxicity. Eur J Cancer 31A:S123, 1995 (suppl 5; abstr)
54. Facchini T, Belpomme D, Kemp G, et al: Amifostine (AMI) selectively protects against cumulative toxicities of cyclophosphamide (C) and cisplatin (P). Eur J Cancer 31A:S107, 1995 (suppl 5; abstr)